Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants.

[1]  J. Pell,et al.  Nonlinear Associations Between Cumulative Dietary Risk Factors and Cardiovascular Diseases, Cancer, and All-Cause Mortality: A Prospective Cohort Study From UK Biobank. , 2021, Mayo Clinic proceedings.

[2]  V. Wong,et al.  Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement , 2021, Hepatology.

[3]  F. Mair,et al.  Association between patterns of alcohol consumption (beverage type, frequency and consumption with food) and risk of adverse health outcomes: a prospective cohort study , 2020, BMC Medicine.

[4]  J. Pell,et al.  The joint association of sarcopenia and frailty with incidence and mortality health outcomes: A prospective study. , 2020, Clinical nutrition.

[5]  I. Mikolasevic,et al.  Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand? , 2020, Canadian journal of gastroenterology & hepatology.

[6]  Andrew A. Li,et al.  Association of Sarcopenia and NAFLD: An Overview , 2020, Clinical liver disease.

[7]  B. Koo,et al.  Association between muscle strength and advanced fibrosis in non‐alcoholic fatty liver disease: a Korean nationwide survey , 2020, Journal of cachexia, sarcopenia and muscle.

[8]  J. Pell,et al.  Grip Strength and Walking Pace and Cardiovascular Disease Risk Prediction in 406,834 UK Biobank Participants. , 2020, Mayo Clinic proceedings.

[9]  A. Chowdhury,et al.  Epidemiology of non-alcoholic and alcoholic fatty liver diseases. , 2020, Translational gastroenterology and hepatology.

[10]  D. J. Kim,et al.  Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators , 2020, European Journal of Clinical Nutrition.

[11]  A. Dhaliwal,et al.  Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice , 2020, Expert review of gastroenterology & hepatology.

[12]  I. Deary,et al.  Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis , 2020, BMJ.

[13]  T. Kellogg,et al.  Evolution of NAFLD and Its Management. , 2019, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[14]  J. Pell,et al.  The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms: a prospective cohort study. , 2019, Age and ageing.

[15]  Chaohui Yu,et al.  Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis , 2019, Hepatology International.

[16]  N. Sattar,et al.  Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts , 2019, BMC Medicine.

[17]  I. Leclercq,et al.  Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! , 2019, Clinical science.

[18]  Hong-Kyu Kim,et al.  Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study , 2018, Gut and liver.

[19]  Sang-Man Jin,et al.  Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7‐Year Longitudinal Study , 2018, Hepatology.

[20]  N. Sattar,et al.  Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease , 2018, BMC Medicine.

[21]  M. Saklayen.  The Global Epidemic of the Metabolic Syndrome , 2018, Current Hypertension Reports.

[22]  D. Altman,et al.  Population attributable fraction , 2018, British Medical Journal.

[23]  C. Thongprayoon,et al.  Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis , 2018, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[24]  Yaw-Wen Chang,et al.  Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. , 2017, Clinical nutrition.

[25]  C. Sudlow,et al.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.

[26]  A. Gasbarrini,et al.  Sarcopenia in Patients with Advanced Liver Disease. , 2017, Current protein & peptide science.

[27]  K. Moriya,et al.  Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[28]  Andrea Ganna,et al.  5 year mortality predictors in 498 103 UK Biobank participants: a prospective population-based study , 2015, The Lancet.

[29]  T. Key,et al.  Physical activity in relation to body size and composition in women in UK Biobank. , 2015, Annals of epidemiology.

[30]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[31]  H. J. Yoo,et al.  Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study , 2014, Hepatology.

[32]  R. Collins.  What makes UK Biobank special? , 2012, The Lancet.

[33]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[34]  B. Gao,et al.  Inflammation‐associated interleukin‐6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin‐10–deficient mice , 2011, Hepatology.

[35]  V. Baert,et al.  Motivators and barriers for physical activity in the oldest old: A systematic review , 2011, Ageing Research Reviews.

[36]  Gregory Kaltsas,et al.  Metabolic syndrome: definitions and controversies , 2011, BMC medicine.

[37]  J. Zmuda,et al.  Epidemiology of myosteatosis , 2010, Current opinion in clinical nutrition and metabolic care.

[38]  J. Veerman,et al.  Categorical versus continuous risk factors and the calculation of potential impact fractions , 2009, Journal of Epidemiology & Community Health.

[39]  Paul L. Huang.  A comprehensive definition for metabolic syndrome , 2009, Disease Models & Mechanisms.

[40]  L. Palmer.  UK Biobank: bank on it , 2007, The Lancet.

[41]  S. Kahn,et al.  Review: The role of insulin resistance in nonalcoholic fatty liver disease. , 2006, The Journal of clinical endocrinology and metabolism.

[42]  R. Ross,et al.  Estimation of skeletal muscle mass by bioelectrical impedance analysis. , 2000, Journal of applied physiology.

[43]  J. Mackenbach.  Health and deprivation. Inequality and the North : by P. Townsend, P. Phillimore and A. Beattie (eds.) Croom Helm Ltd, London, 1987 221 pp., ISBN 0-7099-4352-0, [pound sign]8.95 , 1988 .

[44]  T. Kawaguchi,et al.  Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.

[45]  D. Spiegelman,et al.  The International Journal of Biostatistics The Comparison of Alternative Smoothing Methods for Fitting Non-Linear Exposure-Response Relationships with Cox Models in a Simulation Study , 2011 .